ipamorelin/cjc-1295 dallas therapy cjc-1295 ipamorelin peptide benefits CJC‑ 1295 & Ipamorelin Therapy Buy CJC-1295 No DAC /
Description
Accessed April 2, 2020
However, in a subsequent 24-week trial involving 536 obese participants, AOD 9604 did not achieve statistically robust, clinically meaningful weight-loss outcomes versus placebo, and the obesity-drug development program was discontinued around 2007
PMID: 31058573, PMCID: PMC6590721, DOI: 10.1089/jwh.2018.7364
R.TaslimiN.RezaeiF.AkhondzadehS
T.McLeanP
Ezin et al., 2018)
